Fig. 4.
Implantation of microcapsules producing anti-CD137 mAb results in therapeutic immunity against CT26 colon established carcinomas. Sequential individual follow-up of tumor sizes from mice implanted with 5 × 105 CT26 cells implanted 8 days later with APA microcapsules containing 2A hybridoma cells or with one single 100 μg dose of the purified 2A mAb given also on day 8. Fractions of mice completely rejecting their tumors are included in each graph. In the indicated graphs, microcapsules were implanted in the subcutaneous tissue surrounding the tumor lesion (peritumoral), while when indicated the microcapsules were implanted in the retrocervical region far from the area implanted with the tumor cells (sc)